Home › Alzheimer's Disease › NCT06999434

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Who can join

Ages 18 to 90 · All sexes · Healthy volunteers welcome

Inclusion:

1. Male and Female subjects must be ≥18 and \<90 years of age;
2. Able to understand and provide informed consent prior to study procedures
3. Must be in good health

Exclusion:

1. Less than 18 years of age;
2. Pregnant or breastfeeding;
3. Any significant systemic illness or unstable medical condition;
4. Pre-existing medical conditions or claustrophobic reactions;
5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months);
6. History of a bleeding disorder or are currently taking anticoagulants.

About the study

The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

What is being tested

• [ 18F]3F4AP (drug)
• [18F]MK6240 (drug)
• [11C]PIB (drug)

Sponsor: Yale University · Participants: 105 · Started: May 5, 2025

Contact the study team

• Shannan Henry · Phone: +1 (203) 737-5278
• Kayla Cottiers · Phone: 203-737-7496

Official record on ClinicalTrials.gov — NCT06999434

Locations in the U.S.

Conditions

• Alzheimer's Disease
• Multiple Sclerosis
• Spinal Cord Injuries

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.